Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease.
Identifieur interne : 002583 ( Ncbi/Merge ); précédent : 002582; suivant : 002584Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease.
Auteurs : Susie M D. Henley [Royaume-Uni] ; Edward J. Wild ; Nicola Z. Hobbs ; Chris Frost ; David G. Macmanus ; Roger A. Barker ; Nick C. Fox ; Sarah J. TabriziSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2009.
English descriptors
- KwdEn :
- MESH :
- complications : Huntington Disease.
- etiology : Atrophy.
- methods : Magnetic Resonance Imaging.
- pathology : Atrophy, Brain, Huntington Disease.
- Adult, Brain Mapping, Disease Progression, Humans, Middle Aged, Severity of Illness Index.
Abstract
Therapeutic trials in Huntington's disease (HD) are challenging as clinical progression is slow and variable and reliable biomarkers are lacking. We used magnetic resonance imaging and the brain boundary shift integral to quantify whole-brain atrophy rates over 1 year in early and premanifest HD subjects, and controls. Early HD subjects had statistically significantly (P = 0.007) increased (threefold higher) rates of whole-brain atrophy compared with controls. Higher atrophy rates were associated with longer CAG repeat length. MRI-based measures of whole-brain atrophy may have potential as a measure of progression in HD.
DOI: 10.1002/mds.22485
PubMed: 19243073
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001D94
- to stream PubMed, to step Curation: 001D94
- to stream PubMed, to step Checkpoint: 001A95
Links to Exploration step
pubmed:19243073Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease.</title><author><name sortKey="Henley, Susie M D" sort="Henley, Susie M D" uniqKey="Henley S" first="Susie M D" last="Henley">Susie M D. Henley</name><affiliation wicri:level="3"><nlm:affiliation>Dementia Research Centre, Institute of Neurology, National Hospital for Neurology and Neurosurgery, University College London, Queen Square, London, United Kingdom. shenley@drc.ion.ucl.ac.uk</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Dementia Research Centre, Institute of Neurology, National Hospital for Neurology and Neurosurgery, University College London, Queen Square, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Wild, Edward J" sort="Wild, Edward J" uniqKey="Wild E" first="Edward J" last="Wild">Edward J. Wild</name></author><author><name sortKey="Hobbs, Nicola Z" sort="Hobbs, Nicola Z" uniqKey="Hobbs N" first="Nicola Z" last="Hobbs">Nicola Z. Hobbs</name></author><author><name sortKey="Frost, Chris" sort="Frost, Chris" uniqKey="Frost C" first="Chris" last="Frost">Chris Frost</name></author><author><name sortKey="Macmanus, David G" sort="Macmanus, David G" uniqKey="Macmanus D" first="David G" last="Macmanus">David G. Macmanus</name></author><author><name sortKey="Barker, Roger A" sort="Barker, Roger A" uniqKey="Barker R" first="Roger A" last="Barker">Roger A. Barker</name></author><author><name sortKey="Fox, Nick C" sort="Fox, Nick C" uniqKey="Fox N" first="Nick C" last="Fox">Nick C. Fox</name></author><author><name sortKey="Tabrizi, Sarah J" sort="Tabrizi, Sarah J" uniqKey="Tabrizi S" first="Sarah J" last="Tabrizi">Sarah J. Tabrizi</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="doi">10.1002/mds.22485</idno><idno type="RBID">pubmed:19243073</idno><idno type="pmid">19243073</idno><idno type="wicri:Area/PubMed/Corpus">001D94</idno><idno type="wicri:Area/PubMed/Curation">001D94</idno><idno type="wicri:Area/PubMed/Checkpoint">001A95</idno><idno type="wicri:Area/Ncbi/Merge">002583</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease.</title><author><name sortKey="Henley, Susie M D" sort="Henley, Susie M D" uniqKey="Henley S" first="Susie M D" last="Henley">Susie M D. Henley</name><affiliation wicri:level="3"><nlm:affiliation>Dementia Research Centre, Institute of Neurology, National Hospital for Neurology and Neurosurgery, University College London, Queen Square, London, United Kingdom. shenley@drc.ion.ucl.ac.uk</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Dementia Research Centre, Institute of Neurology, National Hospital for Neurology and Neurosurgery, University College London, Queen Square, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Wild, Edward J" sort="Wild, Edward J" uniqKey="Wild E" first="Edward J" last="Wild">Edward J. Wild</name></author><author><name sortKey="Hobbs, Nicola Z" sort="Hobbs, Nicola Z" uniqKey="Hobbs N" first="Nicola Z" last="Hobbs">Nicola Z. Hobbs</name></author><author><name sortKey="Frost, Chris" sort="Frost, Chris" uniqKey="Frost C" first="Chris" last="Frost">Chris Frost</name></author><author><name sortKey="Macmanus, David G" sort="Macmanus, David G" uniqKey="Macmanus D" first="David G" last="Macmanus">David G. Macmanus</name></author><author><name sortKey="Barker, Roger A" sort="Barker, Roger A" uniqKey="Barker R" first="Roger A" last="Barker">Roger A. Barker</name></author><author><name sortKey="Fox, Nick C" sort="Fox, Nick C" uniqKey="Fox N" first="Nick C" last="Fox">Nick C. Fox</name></author><author><name sortKey="Tabrizi, Sarah J" sort="Tabrizi, Sarah J" uniqKey="Tabrizi S" first="Sarah J" last="Tabrizi">Sarah J. Tabrizi</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Atrophy (etiology)</term><term>Atrophy (pathology)</term><term>Brain (pathology)</term><term>Brain Mapping</term><term>Disease Progression</term><term>Humans</term><term>Huntington Disease (complications)</term><term>Huntington Disease (pathology)</term><term>Magnetic Resonance Imaging (methods)</term><term>Middle Aged</term><term>Severity of Illness Index</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Huntington Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Atrophy</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Magnetic Resonance Imaging</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Atrophy</term><term>Brain</term><term>Huntington Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Brain Mapping</term><term>Disease Progression</term><term>Humans</term><term>Middle Aged</term><term>Severity of Illness Index</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Therapeutic trials in Huntington's disease (HD) are challenging as clinical progression is slow and variable and reliable biomarkers are lacking. We used magnetic resonance imaging and the brain boundary shift integral to quantify whole-brain atrophy rates over 1 year in early and premanifest HD subjects, and controls. Early HD subjects had statistically significantly (P = 0.007) increased (threefold higher) rates of whole-brain atrophy compared with controls. Higher atrophy rates were associated with longer CAG repeat length. MRI-based measures of whole-brain atrophy may have potential as a measure of progression in HD.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">19243073</PMID><DateCreated><Year>2009</Year><Month>05</Month><Day>04</Day></DateCreated><DateCompleted><Year>2009</Year><Month>07</Month><Day>29</Day></DateCompleted><DateRevised><Year>2015</Year><Month>01</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>6</Issue><PubDate><Year>2009</Year><Month>Apr</Month><Day>30</Day></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease.</ArticleTitle><Pagination><MedlinePgn>932-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.22485</ELocationID><Abstract><AbstractText>Therapeutic trials in Huntington's disease (HD) are challenging as clinical progression is slow and variable and reliable biomarkers are lacking. We used magnetic resonance imaging and the brain boundary shift integral to quantify whole-brain atrophy rates over 1 year in early and premanifest HD subjects, and controls. Early HD subjects had statistically significantly (P = 0.007) increased (threefold higher) rates of whole-brain atrophy compared with controls. Higher atrophy rates were associated with longer CAG repeat length. MRI-based measures of whole-brain atrophy may have potential as a measure of progression in HD.</AbstractText><CopyrightInformation>(c) 2009 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Henley</LastName><ForeName>Susie M D</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Institute of Neurology, National Hospital for Neurology and Neurosurgery, University College London, Queen Square, London, United Kingdom. shenley@drc.ion.ucl.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wild</LastName><ForeName>Edward J</ForeName><Initials>EJ</Initials></Author><Author ValidYN="Y"><LastName>Hobbs</LastName><ForeName>Nicola Z</ForeName><Initials>NZ</Initials></Author><Author ValidYN="Y"><LastName>Frost</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>MacManus</LastName><ForeName>David G</ForeName><Initials>DG</Initials></Author><Author ValidYN="Y"><LastName>Barker</LastName><ForeName>Roger A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick C</ForeName><Initials>NC</Initials></Author><Author ValidYN="Y"><LastName>Tabrizi</LastName><ForeName>Sarah J</ForeName><Initials>SJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0601846</GrantID><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001284">Atrophy</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001921">Brain</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001931">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006816">Huntington Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008279">Magnetic Resonance Imaging</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>2</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>2</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>7</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.22485</ArticleId><ArticleId IdType="pubmed">19243073</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li></region><settlement><li>Londres</li></settlement></list><tree><noCountry><name sortKey="Barker, Roger A" sort="Barker, Roger A" uniqKey="Barker R" first="Roger A" last="Barker">Roger A. Barker</name><name sortKey="Fox, Nick C" sort="Fox, Nick C" uniqKey="Fox N" first="Nick C" last="Fox">Nick C. Fox</name><name sortKey="Frost, Chris" sort="Frost, Chris" uniqKey="Frost C" first="Chris" last="Frost">Chris Frost</name><name sortKey="Hobbs, Nicola Z" sort="Hobbs, Nicola Z" uniqKey="Hobbs N" first="Nicola Z" last="Hobbs">Nicola Z. Hobbs</name><name sortKey="Macmanus, David G" sort="Macmanus, David G" uniqKey="Macmanus D" first="David G" last="Macmanus">David G. Macmanus</name><name sortKey="Tabrizi, Sarah J" sort="Tabrizi, Sarah J" uniqKey="Tabrizi S" first="Sarah J" last="Tabrizi">Sarah J. Tabrizi</name><name sortKey="Wild, Edward J" sort="Wild, Edward J" uniqKey="Wild E" first="Edward J" last="Wild">Edward J. Wild</name></noCountry><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Henley, Susie M D" sort="Henley, Susie M D" uniqKey="Henley S" first="Susie M D" last="Henley">Susie M D. Henley</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002583 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 002583 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:19243073
|texte= Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:19243073" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |